Michael J. Borowitz
YOU?
Author Swipe
View article: Integrated machine learning analysis for automatic recognition of b-ALL MRD level in flow cytometry list mode data
Integrated machine learning analysis for automatic recognition of b-ALL MRD level in flow cytometry list mode data Open
Introduction Minimal residual disease (MRD) detection by flow cytometry is a powerful prognostic indicator in B acute lymphoblastic leukemia (B-ALL), but accurately differentiating normal precursor B cells from leukemic cells requires sign…
View article: Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report Open
Pediatric Hispanic and Black patients with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) experience worse overall survival (OS). We hypothesized that differential outcomes by race and ethnicity following relapse may contribut…
View article: Healthy LLMs? Benchmarking LLM Knowledge of UK Government Public Health Information
Healthy LLMs? Benchmarking LLM Knowledge of UK Government Public Health Information Open
As Large Language Models (LLMs) become widely accessible, a detailed understanding of their knowledge within specific domains becomes necessary for successful real world use. This is particularly critical in public health, where failure to…
View article: The real‐world application of T‐cell receptor constant beta‐1 chain antibody assay in cutaneous T‐cell lymphoma
The real‐world application of T‐cell receptor constant beta‐1 chain antibody assay in cutaneous T‐cell lymphoma Open
Summary Identifying aberrant T lymphocytes in peripheral blood is essential for diagnosing Sezary syndrome (SS) and is a prognostic indicator in mycosis fungoides (MF). Flow cytometry using a T‐cell receptor constant beta‐1 chain (TRBC1)‐t…
View article: Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study Open
Limited prognostic factors have been associated with overall survival (OS) post-relapse in childhood Acute Lymphoblastic Leukemia (ALL). Patients enrolled on 12 Children’s Oncology Group frontline ALL trials (1996–2014) were analyzed to as…
View article: Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia Open
PURPOSE Although cure rates for childhood acute lymphoblastic leukemia (ALL) exceed 90%, ALL remains a leading cause of cancer death in children. Half of relapses arise in children initially classified with standard-risk (SR) disease. MATE…
View article: Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report Open
Current strategies to treat pediatric acute lymphoblastic leukemia rely on risk stratification algorithms using categorical data. We investigated whether using continuous variables assigned different weights would improve risk stratificati…
View article: Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group Open
PURPOSE Patients with Down syndrome (DS) and B-ALL experience increased rates of relapse, toxicity, and death. We report results for patients with DS B-ALL enrolled on Children's Oncology Group trials between 2003 and 2019. METHODS We anal…
View article: Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study Open
The early thymic precursor (ETP) immunophenotype was previously reported to confer poor outcome in T-cell acute lymphoblastic leukemia (T-ALL). Between 2009 and 2014, 1256 newly diagnosed children and young adults enrolled in Children’s On…
View article: Minimal residual disease predicts outcomes in <i>KMT2A</i>‐rearranged but not <i>KMT2A</i>‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631
Minimal residual disease predicts outcomes in <i>KMT2A</i>‐rearranged but not <i>KMT2A</i>‐germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631 Open
We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]‐specific methyltransferase 2A)‐rearranged and 58 with KMT2A ‐germline acute lymphoblastic leukemia …
View article: Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse Open
PURPOSE Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a favorable toxicity profile. One aim of the Children's Oncology Group AALL1331 study was to compare survival…
View article: Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia
Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia Open
Trisomy 21, the genetic cause of Down syndrome (DS), is the most common congenital chromosomal anomaly. It is associated with a 20-fold increased risk of acute lymphoblastic leukemia (ALL) during childhood and results in distinctive leukem…
View article: The International Consensus Classification of Acute Leukemias of Ambiguous Lineage
The International Consensus Classification of Acute Leukemias of Ambiguous Lineage Open
Letter to Blood| May 4, 2023 The International Consensus Classification of acute leukemias of ambiguous lineage Olga K. Weinberg, Olga K. Weinberg 1Department of Pathology, University of Texas Southwestern Medical Center Dallas, TX https:/…
View article: Supply chain disruptions due to the SARS‐CoV‐2 pandemic lead to an unusual preanalytical error in measuring hemoglobin concentration in a large medical center
Supply chain disruptions due to the SARS‐CoV‐2 pandemic lead to an unusual preanalytical error in measuring hemoglobin concentration in a large medical center Open
Preanalytical errors are defined as those that occur prior to the testing process (e.g., test request, patient and specimen identification, specimen collection, transport, accessioning and processing) and represent 46–68% of all analytical…
View article: Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia Open
Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these mali…
View article: International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Open
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. Th…
View article: Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells Open
Relapse following chimeric antigen receptor (CAR) T-cell therapy directed against CD19 for relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL) remains a significant challenge. Three main patterns of relapse predominate: CD19 pos…
View article: Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report
Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report Open
Background Boys with acute lymphoblastic leukemia (ALL) have historically experienced inferior survival compared to girls. This study determined whether sex‐based disparities persist with contemporary therapy and whether patterns of treatm…
View article: Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial Open
Not available.
View article: Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium
Remission, treatment failure, and relapse in pediatric ALL: an international consensus of the Ponte-di-Legno Consortium Open
Comparison of treatment strategies in de novo pediatric acute lymphoblastic leukemia (ALL) requires standardized measures of efficacy. Key parameters that define disease-related events, including complete remission (CR), treatment failure …
View article: Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331
Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 Open
PURPOSE Children's Oncology Group (COG) AALL0331 tested whether pegaspargase intensification on a low-intensity chemotherapy backbone would improve the continuous complete remission (CCR) rate in a low-risk subset of children with standard…